sunitinib newbury 50 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 50 mg
sunitinib newbury 12.5 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 12.5 mg
sunitinib newbury 25 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 25 mg
sunitinib teva 12.5 mg
teva b.v. - sunitinib - kapsel, hard - 12.5 mg
sunitinib teva 25 mg
teva b.v. - sunitinib - kapsel, hard - 25 mg
sunitinib teva 50 mg
teva b.v. - sunitinib - kapsel, hard - 50 mg
orserdu
stemline therapeutics b.v. - elacestrant - bryst neoplasms - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
erwinase 10000 e
porton biopharma limited - krisantaspase - pulver til injeksjons-/infusjonsvæske, oppløsning - 10000 e
bosulif 400 mg
abacus medicine a/s - bosutinibmonohydrat - tablett, filmdrasjert - 400 mg
bosulif 100 mg
2care4 aps - bosutinibmonohydrat - tablett, filmdrasjert - 100 mg